Engineered immune cells deliver anticancer signal, prevent cancer from spreading
In a study of mice, treatment with the engineered cells shrank tumors and prevented the cancer from spreading to other parts of the body
Scientists have genetically engineered immune cells, called myeloid cells, to precisely deliver an anticancer signal to organs where cancer may spread. In a study of mice, treatment with the engineered cells shrank tumors and prevented the cancer from spreading to other parts of the body. The study, led by scientists at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health, was published March 24, 2021, in Cell.
“This is a novel approach to immunotherapy that appears to have promise as a potential treatment for metastatic cancer,” said the study’s leader, Rosandra Kaplan, M.D., of NCI’s Center for Cancer Research.
Metastatic cancer — cancer that has spread from its original location to other parts of the body — is notoriously difficult to treat. Dr. Kaplan’s team has been exploring another approach: Preventing cancer from spreading in the first place.
This page was last updated on Friday, January 21, 2022